Portal de Periódicos da CAPES

Brief Report

2015; Lippincott Williams & Wilkins; Volume: 72; Issue: 1 Linguagem: Inglês

10.1097/qai.0000000000000893

1944-7884

K. Tsuchiya, Tsunefusa Hayashida, Akinobu Hamada, Shinichi Oka, Hiroyuki Gatanaga,

HIV Research and Treatment

Raltegravir was recently identified to be a substrate of ATP-binding cassette transporter B1 (ABCB1) and G2 (ABCG2), which are efflux transporters and expressed in the intestines. We analyzed the relations between plasma raltegravir concentrations and single nucleotide polymorphism of ABCB1 and ABCG2 genes. The peak plasma concentration of raltegravir was significantly higher in the patients with ABCB1 4036 AG/GG and ABCG2 421 CA/AA than in other genotype holders (P = 0.0052), though no difference was identified in trough raltegravir concentrations, which may be explained by reduced expression of efflux transporters in intestine by these genetic variants.